RBM17 and acute myeloid leukemia: Above median levels of RBM17 expression is significantly linked to poor outcome of AML patients from the Leucegene dataset (P = 0.034)23 and showed a negative prognostic trend in BeatAML datasets (P = 0.059)17 (Supplementary Fig. 1a-b).